Biomarkers in the management of heart failure

Current Treatment Options in Cardiovascular Medicine

Volumn 12, Issue 6, 2010, Pages 519-531

  Kim, Han Na ^b   Januzzi Jr , James L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GALECTIN 3; HYDRALAZINE; INTERLEUKIN 1 RECEPTOR; NITRATE; PROTEIN ST2; UNCLASSIFIED DRUG;

CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFICACY; DRUG MONITORING; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEMODYNAMIC MONITORING; HUMAN; MORBIDITY; OUTPATIENT CARE; PEPTIDE ANALYSIS; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TREATMENT PLANNING;

EID: 78649907428     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-010-0096-3     Document Type: Review

References (46)

1. V Singh P Martinezclark M Pascual, et al. 2010 Cardiac biomarkers-the old and the new: a review Coron Artery Dis 21 244 256 10.1097/MCA.0b013e328338cd1f 20351549
2. E Braunwald 2008 Biomarkers in heart failure N Engl J Med 358 2148 2159 1:CAS:528:DC%2BD1cXlvFCrsL8%3D 10.1056/NEJMra0800239 18480207 This is a concise and well-organized overview of biomarkers in heart failure (Pubitemid 351679601)
3. Mann DL: Pathophysiology of heart failure. In Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 8. By Libby P, Bonow RO, Mann DL, Zipes DP. Philadelphia: WB Saunders; 2007:546.
4. FL Piao SH Park JH Han, et al. 2004 Dendroaspis natriuretic peptide and its functions in pig ovarian granulosa cells Regul Pept 118 193 198 1:CAS:528:DC%2BD2cXhvFaisr4%3D 10.1016/j.regpep.2003.12.011 15003836 (Pubitemid 38296733)
5. T Omland TA Hagve 2009 Natriuretic peptides: physiologic and analytic considerations Heart Fail Clin 5 471 487 10.1016/j.hfc.2009.04.005 19631173
6. Rubattu S, Sciarretta S, Morriello A, et al.: NPR-C: a component of the natriuretic peptide family with implications in human diseases. J Mol Med 2010 (in press).
7. M Richards RW Troughton 2004 NT-proBNP in heart failure: therapy decisions and monitoring Eur J Heart Fail 6 351 354 1:CAS:528: DC%2BD2cXhsFWqsb4%3D 10.1016/j.ejheart.2004.01.003 14987587 (Pubitemid 38253056)
8. RR van Kimmenade JL Januzzi Jr JA Bakker, et al. 2009 Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects J Am Coll Cardiol 53 884 890 10.1016/j.jacc.2008.11.032 19264247 The fractional extraction rate of BNP and NT-proBNP were measured invasively from 165 patients. It was found that both BNP and NT-proBNP were equally dependent on renal clearance and disproved the popular belief that NT-proBNP was more dependent than BNP on renal function
9. AS Maisel P Krishnaswamy RM Nowak, et al. 2002 Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure N Engl J Med 347 161 167 1:CAS:528:DC%2BD38Xlt12jsL8%3D 10.1056/NEJMoa020233 12124404 (Pubitemid 34764819)
10. JJL Januzzi CA Camargo S Anwaruddin, et al. 2005 The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) study Am J Cardiol 95 948 954 1:CAS:528:DC%2BD2MXjtlWjurs%3D 10.1016/j.amjcard.2004.12.032 15820160 (Pubitemid 40487743)
11. JA Doust E Pietrzak A Dobson, et al. 2005 How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review BMJ 330 625 1:CAS:528:DC%2BD2MXjtlaht74%3D 10.1136/bmj.330.7492.625 15774989
12. Y Michihiro M Yuji N Masafumi, et al. 2002 B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure Am J Med 112 716 720 10.1016/S0002-9343(02)01121-X (Pubitemid 34655660)
13. R Latini S Masson I Anand, et al. 2002 Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT) Circulation 106 2454 2458 1:CAS:528:DC%2BD38XotFKrtbo%3D 10.1161/01.CIR.0000036747.68104.AC 12417542 (Pubitemid 35278801)
14. B Stanek B Frey M Hülsmann, et al. 2001 Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction J Am Coll Cardiol 38 436 442 1:CAS:528: DC%2BD3MXmtF2qt7c%3D 10.1016/S0735-1097(01)01383-3 11499735 (Pubitemid 32721772)
15. WH Jeffrey MY Cheuk Y Gabriel, et al. 2003 Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure Am J Cardiol 92 406 410 10.1016/S0002-9149(03)00658-1 (Pubitemid 36959876)
16. C Berry N Murphy G De Vito, et al. 2007 Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker Eur J Heart Failure 9 429 434 1:CAS:528:DC%2BD2sXjsVeqsrk%3D 10.1016/j.ejheart.2006. 10.005 (Pubitemid 46441973)
17. E Menardi A Vado G Rossetti, et al. 2008 Cardiac resynchronization therapy modifies the neurohormonal profile, hemodynamic and functional capacity in heart failure patients Arch Med Res 39 702 708 1:CAS:528:DC%2BD1cXhtVKlsrfF 10.1016/j.arcmed.2008.07.004 18760200
18. FM Fruhwald A Fahrleitner-Pammer R Berger, et al. 2007 Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony Eur Heart J 28 1592 1597 1:CAS:528:DC%2BD2sXpslKmtL8%3D 10.1093/eurheartj/ehl505 17298973 (Pubitemid 47227112)
19. M Ryder NF Murphy D McCaffrey, et al. 2008 Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure Eur J Heart Failure 10 267 272 10.1016/j.ejheart. 2008.01.003
20. K Maeda T Tsutamoto A Wada, et al. 2000 High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure J Am Coll Cardiology 36 1587 1593 1:CAS:528:DC%2BD3cXosFKgsLg%3D 10.1016/S0735-1097(00)00912-8
21. RV Shah JL Januzzi Jr 2010 ST2: a novel remodeling biomarker in acute and chronic heart failure Curr Heart Fail Rep 7 9 14 1:CAS:528:DC%2BC3cXht1Cjs7fF 10.1007/s11897-010-0005-9 20425491
22. A Bhardwaj JL Januzzi Jr 2010 ST2: a novel biomarker for heart failure Expert Rev Mol Diagn 10 459 464 1:CAS:528:DC%2BC3cXmtVSnsro%3D 10.1586/erm.10.25 20465500
23. S Masson R Latini IS Anand, et al. 2006 Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data Clin Chem 52 1528 1538 1:CAS:528:DC%2BD28XnvFaht7g%3D 10.1373/clinchem.2006.069575 16777915 (Pubitemid 44148316)
24. JL Januzzi Jr R Sakhuja M O'Donoghue, et al. 2006 Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department Arch Intern Med 166 315 320 1:CAS:528:DC%2BD28XhvFOntr8%3D 10.1001/archinte.166.3.315 16476871 (Pubitemid 43244319)
25. DA Pascual-Figal M Domingo T Casas, et al. 2008 Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients Eur Heart J 29 1011 1018 1:CAS:528:DC%2BD1cXmt1ejtLg%3D 10.1093/eurheartj/ehn023 18263871 (Pubitemid 351844674)
26. AH Wu 2006 Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results Am Heart J 152 828 834 1:CAS:528:DC%2BD28XhtFertbzM 10.1016/j.ahj.2006.08.021 17070141 (Pubitemid 44632969)
27. M Schou F Gustafsson PH Nielsen, et al. 2007 Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state Eur J Heart Fail 9 68 74 1:CAS:528:DC%2BD2sXls1yrug%3D%3D 10.1016/j.ejheart.2006.05.001 16829184 (Pubitemid 46074482)
28. A José Paulo A Ana L Patrícia, et al. 2006 Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure Am J Cardiol 98 1248 1250 10.1016/j.amjcard.2006.06. 017 (Pubitemid 44739919)
29. Shah MR: Abstract 2554: STARBRITE: a randomized pilot trial of bnp-guided therapy in patients with advanced heart failure. Circulation 2006, 114(18-MeetingAbstracts):II-528.
30. P Jourdain G Jondeau F Funck, et al. 2007 Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study J Am Coll Cardiol 49 1733 1739 1:CAS:528:DC%2BD2sXksFWqtbg%3D 10.1016/j.jacc.2006.10.081 17448376 (Pubitemid 46589928)
31. M Pfisterer P Buser H Rickli, et al. 2009 BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial JAMA 301 383 392 1:CAS:528:DC%2BD1MXhtlWgsbw%3D 10.1001/jama.2009.2 19176440 This was the first major and largest study published to date of NT-proBNP-guided HF therapy that randomized older patients to biomarker-guided HF management or standard care. It did not show a significant difference in the primary endpoint of survival free of hospitalization for any cause. However, in a prespecified subgroups analysis, patients <75 years of age did benefit from biomarker-guided HF therapy whereas patients ≥75 years did not. This was the first study to suggest age modified outcomes of biomarker-guided HF therapy
32. JG Lainchbury RW Troughton KM Strangman, et al. 2009 N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial J Am Coll Cardiol 55 53 60 10.1016/j.jacc.2009.02.095 20117364 This study randomized 364 HF patients to NT-proBNP-guided management, intensive care, or standard care and found that at 1 year, the NT-proBNP group and the intensive care group had improved mortality compared with the standard care group. However at 3 years, in patients ≥75 years, the NT-proBNP group had the best mortality rate compared with both the intensive and the standard care group
33. JG Cleland AP Coletta AL Clark, et al. 2009 Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA Eur J Heart Fail 11 622 630 10.1093/eurjhf/hfp071 19468023
34. R Berger D Moertl S Peter, et al. 2010 N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study J Am Coll Cardiol 55 645 653 1:CAS:528:DC%2BC3cXjslKgsrw%3D 10.1016/j.jacc.2009.08. 078 20170790 This randomized, three-arm trial showed that NT-proBNP-guided HF therapy improved HF outcomes beyond intensified, multidisciplinary care of HF patients or standard HF therapy alone
35. GM Felker V Hasselblad AF Hernandez, et al. 2009 Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials Am Heart J 158 422 430 1:CAS:528:DC%2BD1MXhtVegs7fP 10.1016/j.ahj.2009.06.018 19699866 This was the first major meta-analysis that looked at 1627 HF patients in prospective, randomized controlled trials and found a 31% reduction in all-cause mortality with biomarker-guided HF therapy over standard care
36. P Porapakkham H Zimmet B Billah, et al. 2010 B-type natriuretic peptide-guided heart failure therapy: a meta-analysis Arch Intern Med 170 507 514 1:CAS:528:DC%2BC3cXksFSqsbo%3D 10.1001/archinternmed.2010.35 20308637 This meta-analysis of prospective, randomized controlled trials confirmed the all-cause mortality benefit to biomarker-guided HF therapy over standard care with a 24% reduction in death
37. M Schou F Gustafsson L Videbaek, et al. 2008 Design and methodology of the NorthStar Study: NT-proBNP stratified follow-up in outpatient heart failure clinics-a randomized Danish multicenter study Am Heart J 156 649 655 1:CAS:528:DC%2BD1cXhtFOgt7zP 10.1016/j.ahj.2008.06.007 18946891
38. A Bhardwaj SU Rehman A Mohammed, et al. 2010 Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study Am Heart J 159 532 538 e1 1:CAS:528:DC%2BC3cXktlCjsrs%3D 10.1016/j.ahj.2010.01.005 20362709
39. ClinicalTrials.gov: Improvement of Patients With Chronic Heart Failure Using NT-proBNP (EXIMPROVECHF). Available at http://www.clinicaltrials.gov/ct2/ show/NCT00601679?term=NT-probnp&rank=1. Accessed June 3, 2010.
40. ClinicalTrials.gov: Evaluation of Heart Failure Treatment Guided by NTproBNP vs Clinical Symptoms and Signs Alone. Available at http://www. clinicaltrials.gov/ct2/show/NCT00391846?term=Persson&rank=4. Accessed June 3, 2010.
41. WC Members SA Hunt WT Abraham, et al. 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation Circulation 2009 119 e391 479
42. Heart Failure Society of America 2010 Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline J Cardiac Failure 16 475 539 10.1016/j.cardfail.2010.04.005
43. JN Cohn SW Tam IS Anand, et al. 2007 Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT J Card Fail 13 331 339 1:CAS:528:DC%2BD2sXntF2rur8%3D 10.1016/j.cardfail.2007.03.001 17602978 (Pubitemid 46978420)
44. LS Marcus D Hart M Packer, et al. 1996 Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial Circulation 94 3184 3189 1:CAS:528:DyaK2sXks12quw%3D%3D 8989127
45. DM Heublein BK Huntley G Boerrigter, et al. 2007 Immunoreactivity and guanosine 3′, 5′-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide Hypertension 49 1114 1149 1:CAS:528:DC%2BD2sXktFagsbs%3D 10.1161/HYPERTENSIONAHA.106.081083 17372040 (Pubitemid 351664304)
46. A Manginas A Tsiavou P Sfyrakis, et al. 2009 Increased number of circulating progenitor cells after implantation of ventricular assist devices J Heart Lung Transplant 28 710 717 10.1016/j.healun.2009.04.006 19560700